Pre-Market Trading Up in Final Session of the Week

Pre-Market Trading Up in Final Session of the Week

Friday, July 31st, 2026

Following yesterday’s Personal Consumption Expenditures (PCE) and Wednesday’s Fed meeting an press conference with Fed Chair Kevin Warsh, we quiet down ahead of the final trading session for the week. Despite some mid-week turbulence, we’re trading fairly even with where we were as of mid-day Monday. The Dow is +179 points at this hour, the S&P 500 +12 and the Nasdaq +241 points.

Q2 Employment Costs are out this morning, but unlikely to move the needle in terms of trading sentiment. The headline +0.9% matches the previous quarter and +10 basis points (bps) from expectations. Wages and salaries for civilian workers came in at +3.2%, benefits +3.8%. For state and local government workers, this adjusts to +3.6%.
 

Q2 Earnings at a Glance: ABBV, XOM & More


AbbVie ABBV shares are trading down at this hour, following a beat by a penny on the bottom line to $3.65 per share on revenues of $16.99 billion, +1.07%. The Big Pharma staple has not missed on earnings since 2018. But full-year earnings guidance was pulled lower than current projections, and shares are down -4% presently. For more on ABBV’s earnings, click here.

A pair of International Integrated Oil & Gas “supermajors” also reported earnings this morning. ExxonMobil XOM posted a negative earnings surprise of -4.35% on lower quarterly oil production, for its second miss in the past four quarter. Chevron CVX beat estimates by +4.48%. Both companies blasted past revenues estimates by +21%, though only Chevron is trading higher.
For more on XOM’s earnings, click here.
For more on CVX’s earnings, click here.

Colgate-Palmolive CL outpaced earnings estimates, $0.99 per share versus $0.95, even though higher tariff costs dampened the household products major’s outlook. Revenues were fairly in-line with estimates at $5.36 billion, above the $5.11 billion reported a year ago. Shares are down -1.8% at this hour. For more on CL’s earnings, click here.

Questions or comments about this article and/or author? Click here>>

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Chevron Corporation (CVX): Free Stock Analysis Report
 
ExxonMobil Holdings Corporation (XOM): Free Stock Analysis Report
 
Colgate-Palmolive Company (CL): Free Stock Analysis Report
 
AbbVie Inc. (ABBV): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research